Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia

References

• Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16(17):2581–2588.
   PubMed Web of Science ®Google Scholar
• Antonsdottir IM, Smith J, Keltz M, et al. Advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16(11):1649–1656.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–1254.
   PubMed Web of Science ®Google Scholar
• Brown R, Howard R, Candy B, et al. Opioids for agitation in dementia. Cochrane Database Syst Rev. 2015;5:CD009705.
   Google Scholar
• Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37(8):1363–1379.
   PubMed Web of Science ®Google Scholar
• Bali V, Chatterjee S, Carnahan RM, et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv. 2015;66(12):1333–1340.
   PubMed Web of Science ®Google Scholar
• Wang C, Gao S, Hendrie HC, et al. Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord. 2015 Aug 19;1. [Epub ahead of print].
   Google Scholar
• Goveas JS, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women’s Health Initiative Memory Study. Int Psychogeriatr. 2012;24(8):1252–1264.
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Lucicesare A, et al. Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort. Am J Geriatr Psychiatry. 2008;16(10):834–843.
   PubMed Web of Science ®Google Scholar
• Saczynski JS, Rosen AB, McCammon RJ, et al. Antidepressant use and cognitive decline: the health and retirement study. Am J Med. 2015;128(7):739–746.
   PubMed Web of Science ®Google Scholar
• Butters MA, Becker JT, Nebes RD, et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157:1949–1954.
   PubMed Web of Science ®Google Scholar
• Mandelli L, Serretti A, Colombo C, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. 2006;60:598–604.
   PubMed Web of Science ®Google Scholar
• Culang ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. 2009;17:881–888.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. 2011;26(6):316–322.
   PubMed Web of Science ®Google Scholar
• Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317–1324.
   PubMedGoogle Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Ellul J, Archer N, Foy CM, et al. The effects of commonly prescribed drugs in patients with Alzheimer’s disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2007;78(3):233–239.
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry. 2012;27(12):1248–1257.
   PubMed Web of Science ®Google Scholar
• Li XL, Hu N, Tan MS, et al. Behavioral and psychological symptoms in Alzheimer’s disease. Biomed Res Int. 2014;2014:927804.
   PubMedGoogle Scholar
• Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–608.
   PubMed Web of Science ®Google Scholar
• Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
   PubMedGoogle Scholar
• Ford AH. Neuropsychiatric aspects of dementia. Maturitas. 2014;79(2):209–215.
   PubMed Web of Science ®Google Scholar
• Borsje P, Wetzels RB, Lucassen PL, et al. The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review. Int Psychogeriatr. 2015;27(3):385–405.
   PubMed Web of Science ®Google Scholar
• Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2015;190:264–271.
   PubMed Web of Science ®Google Scholar
• Selbæk G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc. 2013;14(3):161–169.
   PubMed Web of Science ®Google Scholar
• Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010;58(2):330–337.
   PubMed Web of Science ®Google Scholar
• Thyrian JR, Eichler T, Hertel J, et al. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care: results of the DelpHi-study. J Alzheimers Dis. 2015;46(2):451–459.
   PubMed Web of Science ®Google Scholar
• Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–481.
   PubMed Web of Science ®Google Scholar
• Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460–465.
   PubMed Web of Science ®Google Scholar
• Moore A, Patterson C, Lee L, et al. Fourth Canadian consensus conference on the diagnosis and treatment of dementia: recommendations for family physicians. Can Fam Physician. 2014;60(5):433–438.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Zuidema SU, Johansson A, Selbæk G, et al. A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. Int Psychogeriatr. 2015;27(11):1849–1859.
   PubMed Web of Science ®Google Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769. Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia
   PubMed Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7–17.
   PubMed Web of Science ®Google Scholar
• McClam TD, Marano CM, Rosenberg PB, et al. Interventions for neuropsychiatric symptoms in neurocognitive impairment due to Alzheimer’s disease: a review of the literature. Harv Rev Psychiatry. 2015;23(5):377–393.
   PubMed Web of Science ®Google Scholar
• Koponen M, Taipale H, Tanskanen A, et al. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study. Eur Neuropsychopharmacol. 2015;25(10):1706–1713.
   PubMed Web of Science ®Google Scholar
• Bishara D, Taylor D, Howard RJ, et al. Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK. Int J Geriatr Psychiatry. 2009;24(9):944–954.
   PubMed Web of Science ®Google Scholar
• Rattinger GB, Burcu M, Dutcher SK, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723–733.
   PubMed Web of Science ®Google Scholar
• Xiao H, Su Y, Cao X, et al. A meta-analysis of mood stabilizers for Alzheimer’s disease. J Huazhong Univ Sci Technolog Med Sci. 2010;30(5):652–658.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565–574.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553–563.
   PubMed Web of Science ®Google Scholar
• Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213–218.
   PubMed Web of Science ®Google Scholar
• Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.
   PubMedGoogle Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 2005;294(15):1934–1943.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.
   PubMed Web of Science ®Google Scholar
• Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915–937.
   PubMed Web of Science ®Google Scholar
• Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimers Res Ther. 2015;7(1):20.
   PubMed Web of Science ®Google Scholar
• Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–445.
   PubMed Web of Science ®Google Scholar
• Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–970.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry. 2014;4(4):72–79.
   PubMedGoogle Scholar
• Ismail Z, Nguyen MQ, Fischer CE, et al. Neurobiology of delusions in Alzheimer’s disease. Curr Psychiatry Rep. 2011;13(3):211–218.
   PubMed Web of Science ®Google Scholar
• Whitehead D, Tunnard C, Hurt C, et al. Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer’s disease. Int Psychogeriatr. 2012;24(1):99–107.
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76 Pt A:27–50.
   PubMed Web of Science ®Google Scholar
• Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer’s disease? CNS Neurosci Ther. 2010;16(4):235–245.
   PubMed Web of Science ®Google Scholar
• Xu Y, Yan J, Zhou P, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol. 2012;97(1):1–13.
   PubMed Web of Science ®Google Scholar
• Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555–563.
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375–399.
   PubMed Web of Science ®Google Scholar
• Tata AM, Velluto L, D’Angelo C, et al. Cholinergic system dysfunction and neurodegenerative diseases: cause or effect? CNS Neurol Disord Drug Targets. 2014;13(7):1294–1303.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203.
   PubMed Web of Science ®Google Scholar
• Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011;221(2):334–340.
   PubMed Web of Science ®Google Scholar
• Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99(2):254–261.
   PubMed Web of Science ®Google Scholar
• Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res Rev. 2011;10(4):404–412.
   PubMed Web of Science ®Google Scholar
• Dagytė G, Den Boer JA, Trentani A. The cholinergic system and depression. Behav Brain Res. 2011;221(2):574–582.
   PubMed Web of Science ®Google Scholar
• Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52(6):1052–1060.
   PubMed Web of Science ®Google Scholar
• Vermeiren Y, Van Dam D, Aerts T, et al. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2014;41(3):819–833.
   PubMed Web of Science ®Google Scholar
• Vermeiren Y, Van Dam D, Aerts T, et al. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther. 2015;7(1):7.
   PubMed Web of Science ®Google Scholar
• Hirao K, Pontone GM, Smith GS. Molecular imaging of neuropsychiatric symptoms in Alzheimer’s and Parkinson’s disease. Neurosci Biobehav Rev. 2015;49:157–170.
   PubMed Web of Science ®Google Scholar
• Solas M, Puerta E, Ramirez MJ. Treatment options in Alzheimer´s disease: the GABA story. Curr Pharm Des. 2015 Sep 14;21:4960–4971. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Ross JA, McGonigle P, Van Bockstaele EJ. Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer’s disease. Neurobiology of Stress. 2015;2:73–84.
   PubMedGoogle Scholar
• Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–449.
   PubMed Web of Science ®Google Scholar
• Proitsi P, Lupton MK, Reeves SJ, et al. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging. 2012;33(4):791–803.
   PubMed Web of Science ®Google Scholar
• Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014;19(2):121–133.
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Tsang SW, Gil-Bea FJ, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging. 2006;27(8):1110–1117.
   PubMed Web of Science ®Google Scholar
• Pytliak M, Vargová V, Mechírová V, et al. Serotonin receptors - from molecular biology to clinical applications. Physiol Res. 2011;60(1):15–25.
   PubMed Web of Science ®Google Scholar
• Hornung J-P. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26(4):331–343.
   PubMed Web of Science ®Google Scholar
• Kroeze Y, Zhou H, Homberg JR. The genetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2012;136(3):375–400.
   PubMed Web of Science ®Google Scholar
• Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol. 2012;99(1):15–41.
   PubMed Web of Science ®Google Scholar
• Seyedabadi M, Fakhfouri G, Ramezani V, et al. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Exp Brain Res. 2014;232(3):723–738.
   PubMed Web of Science ®Google Scholar
• Meneses A. Serotonin, neural markers, and memory. Front Pharmacol. 2015;6:143.
   PubMed Web of Science ®Google Scholar
• Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev Neurosci. 2013;24(6):629–664.
   PubMed Web of Science ®Google Scholar
• Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J Clin Psychopharmacol. 2012;32(1):83–94.
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5–21.
   PubMed Web of Science ®Google Scholar
• Pritchard AL, Pritchard CW, Bentham P, et al. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24(3):201–206.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009;17(10):839–846.
   PubMed Web of Science ®Google Scholar
• Fidalgo S, Ivanov DK, Wood SH. Serotonin: from top to bottom. Biogerontology. 2013;14(1):21–45.
   PubMed Web of Science ®Google Scholar
• Meneses A. Do serotonin(1-7) receptors modulate short and long-term memory? Neurobiol Learn Mem. 2007;87(4):561–572.
   PubMed Web of Science ®Google Scholar
• Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res. 2008;195(1):17–29.
   PubMed Web of Science ®Google Scholar
• Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108(36):14968–14973.
   PubMed Web of Science ®Google Scholar
• Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6(236):236re4.
   PubMed Web of Science ®Google Scholar
• Hashimoto G, Sakurai M, Teich AF, et al. 5-HT₄ receptor stimulation leads to soluble AβPPα production through MMP-9 upregulation. J Alzheimers Dis. 2012;32(2):437–445.
   PubMed Web of Science ®Google Scholar
• Tesseur I, Pimenova AA, Lo AC, et al. Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice. Neurobiol Aging. 2013;34(7):1779–1789.
   PubMed Web of Science ®Google Scholar
• Giannoni P, Gaven F, De Bundel D, et al. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease. Front Aging Neurosci. 2013;5:96.
   PubMed Web of Science ®Google Scholar
• Pimenova AA, Thathiah A, De Strooper B, et al. Regulation of amyloid precursor protein processing by serotonin signaling. PLoS One. 2014;9(1):e87014.
   Google Scholar
• Geldenhuys WJ, Van Der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease. Expert Rev Neurother. 2009;9(7):1073–1085.
   PubMed Web of Science ®Google Scholar
• Bali A, Singh S. Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance. Curr Top Med Chem. 2015;15(17):1643–1662.
   PubMed Web of Science ®Google Scholar
• Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(12):1515–1528.
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13(11):1092–1099.
   PubMed Web of Science ®Google Scholar
• Meneses A. Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative. Rev Neurosci. 2014;25(3):325–356.
   PubMed Web of Science ®Google Scholar
• Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res. 2008;195(1):30–38.
   PubMed Web of Science ®Google Scholar
• Ramirez MJ, Lai MK, Tordera RM, et al. Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: rationale and current status. Drugs. 2014;74(7):729–736.
   PubMed Web of Science ®Google Scholar
• Claeysen S, Bockaert J, Giannoni P. Serotonin: a new hope in Alzheimer’s disease? ACS Chem Neurosci. 2015;6(7):940–943.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789–797.
   PubMed Web of Science ®Google Scholar
• Hughes LE, Rittman T, Regenthal R, et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138(Pt 7):1961–1975.
   PubMed Web of Science ®Google Scholar
• Flo E, Gulla C, Husebo BS. Effective pain management in patients with dementia: benefits beyond pain? Drugs Aging. 2014;31(12):863–871.
   PubMed Web of Science ®Google Scholar
• Gilmartin JF, Väätäinen S, Törmälehto S, et al. Depressive symptoms are associated with analgesic use in people with Alzheimer’s disease: Kuopio ALSOVA study. PLoS One. 2015;10(2):e0117926.
   Google Scholar
• Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199–212.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59–67.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;212:87–124.
   PubMedGoogle Scholar
• Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169–183.
   PubMed Web of Science ®Google Scholar
• Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.
   Google Scholar
• Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894–901.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460–465.
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Depression and Alzheimer’s disease: symptom or comorbidity? Am J Alzheimers Dis Other Demen. 2002;17(6):338–344.
   PubMedGoogle Scholar
• Scharre DW, Davis RA, Warner JL, et al. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(6):687–691.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15(11):942–952.
   PubMed Web of Science ®Google Scholar
• Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s disease. J Clin Psychiatry. 2009;70(6):915–918.
   PubMed Web of Science ®Google Scholar
• Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):360–364.
   PubMed Web of Science ®Google Scholar
• Barak Y, Plopski I, Tadger S, et al. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515–1519.
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 2014;311(7):682–691.
   PubMed Web of Science ®Google Scholar
• Shua-Haim JR, Shua-Haim V, Ross JS. Combination therapy with donepezil and sertraline in the treatment of Alzheimer’s disease. Alzheimers Reports. 1998;1(5):303–308.
   Google Scholar
• Gaber S, Ronzoni S, Bruno A, et al. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr. 2001;Suppl.: 7:159–162.
   Google Scholar
• Lanctôt KL, Herrmann N, Van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531–541.
   PubMed Web of Science ®Google Scholar
• Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9–18.
   PubMed Web of Science ®Google Scholar
• Olafsson K, Jørgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992;85(6):453–456.
   PubMed Web of Science ®Google Scholar
• Teranishi M, Kurita M, Nishino S, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol. 2013;33(5):600–607.
   PubMed Web of Science ®Google Scholar
• Ramadan FH, Naughton BJ, Bassanelli AG. Treatment of verbal agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol. 2000;13(2):56–59.
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13–19.
   PubMed Web of Science ®Google Scholar
• Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400–408.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Dewan V, Wengel SP, et al. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry. 1997;12(5):519–525.
   PubMed Web of Science ®Google Scholar
• Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer’s disease. J Clin Psychiatry. 1994;55(12):536–538.
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5(1):60–69.
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc. 2001;49(10):1294–1300.
   PubMed Web of Science ®Google Scholar
• Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271–1278.
   PubMed Web of Science ®Google Scholar
• Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–359.
   PubMed Web of Science ®Google Scholar
• Bergh S, Selbæk G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. Bmj. 2012;344:e1566.
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Drye LT, Porsteinsson AP, et al. Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015;27(12):2059–2067.
   PubMed Web of Science ®Google Scholar
• Bardell A, Lau T, Fedoroff JP. Inappropriate sexual behavior in a geriatric population. Int Psychogeriatr. 2011;23(7):1182–1188.
   PubMed Web of Science ®Google Scholar
• Stubbs B. Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour? J Psychiatr Ment Health Nurs. 2011;18(7):602–607.
   PubMed Web of Science ®Google Scholar
• Joller P, Gupta N, Seitz DP, et al. Approach to inappropriate sexual behaviour in people with dementia. Can Fam Physician. 2013;59(3):255–260.
   PubMed Web of Science ®Google Scholar
• Tosto G, Talarico G, Lenzi GL, et al. Effect of citalopram in treating hypersexuality in an Alzheimer’s disease case. Neurol Sci. 2008;29(4):269–270.
   PubMed Web of Science ®Google Scholar
• Chen ST. Treatment of a patient with dementia and inappropriate sexual behaviors with citalopram. Alzheimer Dis Assoc Disord. 2010;24(4):402–403.
   PubMed Web of Science ®Google Scholar
• Kim KY, Bader GM, Jones E. Citalopram for verbal agitation in patients with dementia. J Geriatr Psychiatry Neurol. 2000;13(2):53–55.
   PubMed Web of Science ®Google Scholar
• Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–1574.
   PubMed Web of Science ®Google Scholar
• McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014;3:CD009178.
   PubMedGoogle Scholar
• Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;4:CD004990.
   Google Scholar
• Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29(4):254–263.
   PubMedGoogle Scholar
• Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2002;4:CD003944.
   Google Scholar
• Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: a metaanalysis. Can J Psychiatry. 2007;52(4):248–255.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–585.
   PubMed Web of Science ®Google Scholar
• Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging. 2012;29(10):793–806.
   PubMed Web of Science ®Google Scholar
• Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry. 1989;146(1):45–49.
   PubMed Web of Science ®Google Scholar
• Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86(2):138–145.
   PubMed Web of Science ®Google Scholar
• Volicer L, Rheaume Y, Cyr D. Treatment Of Depression In Advanced Alzheimers-Disease Using Sertraline. J Geriatr Psychiatry Neurol. 1994;7(4):227–229.
   PubMed Web of Science ®Google Scholar
• Petracca G, Tesón A, Chemerinski E, et al. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):270–275.
   PubMed Web of Science ®Google Scholar
• Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics. 1997;38(3):246–252.
   PubMed Web of Science ®Google Scholar
• Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13(2):100–108.
   PubMed Web of Science ®Google Scholar
• Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease. Am J Geriatr Psychiatry. 2000;8(1):66–74.
   PubMed Web of Science ®Google Scholar
• Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease. Int Psychogeriatr. 2001;13(2):233–240.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737–746.
   PubMed Web of Science ®Google Scholar
• Mizukami K, Tanaka Y, Asada T. Efficacy of milnacipran on the depressive state in patients with Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1342–1346.
   PubMed Web of Science ®Google Scholar
• De Vasconcelos Cunha UG, Lopes Rocha F, Avi La De Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord. 2007;24(1):36–41.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332–340.
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–145.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–411.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7):1–166.
   PubMed Web of Science ®Google Scholar
• Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28):1-iv.
   PubMed Web of Science ®Google Scholar
• Diniz BS. Reynolds CF 3rd. Major depressive disorder in older adults: benefits and hazards of prolonged treatment. Drugs Aging. 2014;31(9):661–669.
   PubMed Web of Science ®Google Scholar
• Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11(6):883–892.
   PubMed Web of Science ®Google Scholar
• Spigset O, Wilhelmsson C, Mjörndal T, et al. Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status. J Clin Psychopharmacol. 2000;20(5):582–584.
   PubMed Web of Science ®Google Scholar
• Soysal P, Isik AT. Severe hyponatremia due to escitalopram treatment in an elderly adult with Alzheimer’s disease. J Am Geriatr Soc. 2014;62(12):2462–2463.
   PubMed Web of Science ®Google Scholar
• Tsai PH, Chen HC, Liao SC, et al. Recurrent escitalopram-induced hyponatremia in an elderly woman with dementia with Lewy bodies. Gen Hosp Psychiatry. 2012;34(1):101.e5-7.
   Google Scholar
• Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). [2011; cited 2015 Nov 08]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.
   Google Scholar
• Drye LT, Spragg D, Devanand DP, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS One. 2014;9(6):e98426.
   PubMedGoogle Scholar
• Lee YC, Lin CH, Lin MS, et al. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33(6):782–789.
   PubMed Web of Science ®Google Scholar
• Trifirò G, Dieleman J, Sen EF, et al. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. J Clin Psychopharmacol. 2010;30(3):252–258.
   PubMed Web of Science ®Google Scholar
• Wu CS, Chang CM, Chen CY, et al. Association between antidepressants and venous thromboembolism in Taiwan. J Clin Psychopharmacol. 2013;33(1):31–37.
   PubMed Web of Science ®Google Scholar
• Wang MT, Chu CL, Yeh CB, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J Clin Psychiatry. 2015;76(7):e877–885.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–109.
   PubMed Web of Science ®Google Scholar
• Magierski R, Sobow T. Benefits and risks of add-on therapies for Alzheimer’s disease. Neurodegener Dis Manag. 2015;5(5):445–462.
   PubMedGoogle Scholar
• Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases. Transl Psychiatry. 2013;3:e332.
   Google Scholar
• Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;4:CD009524.
   PubMed Web of Science ®Google Scholar
• Galimberti D, Scarpini E. Idalopirdine as a treatment for Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24(7):981–987.
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Marcinkowska M, Bucki A, et al. Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014;57(11):4543–4557.
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Mierzejewski P, Bieńkowski P, et al. ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility. Br J Pharmacol. 2014;171(4):973–984.
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Marcinkowska M, Bucki A, et al. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem. 2015;92:221–235.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–539.
   PubMedGoogle Scholar
• De Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984–994.
   PubMed Web of Science ®Google Scholar
• Forrester SN, Gallo JJ, Smith GS, et al. Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry. 2016;24(2):117–125.
   PubMed Web of Science ®Google Scholar
• Leoutsakos JM, Forrester SN, Lyketsos CG, et al. Latent classes of neuropsychiatric symptoms in NACC controls and conversion to mild cognitive impairment or dementia. J Alzheimers Dis. 2015;48(2):483–493.
   PubMed Web of Science ®Google Scholar
• David ND, Lin F, Porsteinsson AP; Alzheimer’s Disease Neuroimaging Initiative. Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment. Am J Geriatr Psychiatry. 2016;24(1):70–80.
   PubMed Web of Science ®Google Scholar
• Trzepacz PT, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. Int Psychogeriatr. 2013;25(5):707–719.
   PubMed Web of Science ®Google Scholar